Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908707 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women
A Phase 1 study, sponsored by Laekna Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06908707 is a Phase 1 study that has completed, run by Laekna Limited. The registered enrollment target is 32 participants.
The verdict
NCT06908707, a Phase 1 study, has completed, sponsored by Laekna Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
Interventions
- DRUG Placebo IV
- DRUG Placebo SC
- DRUG LAE102 SC
- DRUG LAE102 IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2025-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06908707
The ClinicalTrials.gov registry entry for NCT06908707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laekna Limited, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo IV is the first listed.
NCT06908707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06908707 about?
NCT06908707 is a clinical study titled "A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women". The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of LAE102 in healthy postmenopausal women
What is the current status of trial NCT06908707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-04-22. Estimated completion is 2025-10-23.
What interventions are being tested in trial NCT06908707?
The interventions under investigation include: Placebo IV (DRUG), Placebo SC (DRUG), LAE102 SC (DRUG), LAE102 IV (DRUG).
Who is sponsoring clinical trial NCT06908707?
This trial is sponsored by Laekna Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.